Parathyroid hormone variability parameters for identifying high turnover osteodystrophy disease in hemodialysis patients: An observational retrospective cohort study

Therapeutic Apheresis and Dialysis

Volumn 14, Issue 6, 2010, Pages 566-571

  De Paola, Luciano ^a   Coppolino, Giuseppe ^a,b   Bolignano, Davide ^b   Buemi, Michele ^b   Lombardi, Luigi ^a  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Hemodialysis; High turnover osteopathy; Parathyroid hormone; Renal osteodystrophy

Indexed keywords

ALBUMIN; AMINOTRANSFERASE; C REACTIVE PROTEIN; CALCIUM; CHOLESTEROL; CREATININE; FERRITIN; FIBRINOGEN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN; LIOTHYRONINE; PARATHYROID HORMONE; PHOSPHATE; POTASSIUM; SODIUM; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD CELL COUNT; COHORT ANALYSIS; FEMALE; FOLLOW UP; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HEMATOCRIT; HEMODIALYSIS; HIGH TURNOVER OSTEODYSTROPHY; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OSTEODYSTROPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE; UREA NITROGEN BLOOD LEVEL;

AGED; BICARBONATES; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 78651478330     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2010.00822.x     Document Type: Article

References (21)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
2. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69.
3. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl: 2003;85:S105-10.
4. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int 1993;43:436-42.
5. Eknoyan G, Levin NW. Impact of the new K/DOQI guidelines. Blood Purif 2002;20:103-8.
6. Bervoets AR, Spasovsky GB, Behets GJ et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. AmJKidneyDis 2003; 41:997-1007.
7. Haas M, Leko-Mohr Z, Roschger P et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 2002;39:580-6.
8. Schwarz C, Sulzbacher I, Oberbauer R. Diagnosis of renal osteodystrophy. Eur J Clin Invest 2006;36:Suppl 2:13-22.
9. Martin KJ, Olgaard K, Coburn JW et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004;43:558-65.
10. Regidor DL, Kovesdy CP, Mehrotra R et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008;19:2193-203.
11. Coen G, Ballanti P, Bonucci E et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998;13:2294-302.
12. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007;18:3164-70.
13. Arneson TJ, Zaun D, Peng Y, Solid CA, Dunning S, Gilbertson DT. Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population. Nephrol Dial Transplant 2009;24:1378-83.
14. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-53.
15. Ferreira A, Drueke TB. Biological markers in the diagnosis of the different forms of renal osteodystrophy. AmJMedSci 2000;320:85-9.
16. Torres A, Lorenzo V, Hernández D et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995;47:1434-42.
17. Lotinun S, Sibonga JD, Turner RT. Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Endocrine 2002;17:29-36.
18. Hodsman AB, Hanley DA, Ettinger MP et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88:5212-20.
19. Lowry MB, Lotinun S, Leontovich AA et al. Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phos-phoinositide 3-kinase-dependent signaling pathway in a rat model for chronic hyperparathyroidism. Endocrinology 2008; 149:5735-46.
20. Hutchison AJ, Whitehouse RW, Boulton HF et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993;44:1071-7.